7 1013

Cited 19 times in

c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5

DC Field Value Language
dc.contributor.author김주항-
dc.contributor.author송재진-
dc.date.accessioned2014-12-18T08:25:49Z-
dc.date.available2014-12-18T08:25:49Z-
dc.date.issued2013-
dc.identifier.issn0929-1903-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/86291-
dc.description.abstractWe previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways. One way is to block the rapid degradation of TRAIL receptors, which can sustain TRAIL-induced apoptosis for a long time. Here, we designed a replication-defective adenovirus expressing the short hairpin RNA (shRNA) against c-Cbl to test the possibility of developing a cancer gene therapy that can act as a sensitizer of TRAIL. As expected from the results of our previous study that used a stable cell line with downregulated c-Cbl, infection with the c-Cbl shRNA-expressing adenovirus led to an increase in the death receptor 4 (DR4) and DR5 levels, which is known to be a cause for the increase of TRAIL-induced apoptosis. In conclusion, we demonstrated that c-Cbl shRNA-expressing adenovirus is able to sensitize TRAIL-induced apoptosis in vivo as well as in vitro.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfCANCER GENE THERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titlec-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5-
dc.typeArticle-
dc.contributor.collegeResearcher Institutes (부설 연구소)-
dc.contributor.departmentInstitute for Cancer Research (암연구소)-
dc.contributor.googleauthorS Y Kim-
dc.contributor.googleauthorJ-H Kim-
dc.contributor.googleauthorJ J Song-
dc.identifier.doi10.1038/cgt.2012.88-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00945-
dc.contributor.localIdA02056-
dc.relation.journalcodeJ00442-
dc.identifier.eissn1476-5500-
dc.identifier.pmidc-Cbl ; TRAIL ; DR4/5 ; shRNA-
dc.identifier.urlhttp://www.nature.com/cgt/journal/v20/n2/full/cgt201288a.html-
dc.subject.keywordc-Cbl-
dc.subject.keywordTRAIL-
dc.subject.keywordDR4/5-
dc.subject.keywordshRNA-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameSong, Jae Jin-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorSong, Jae Jin-
dc.rights.accessRightsnot free-
dc.citation.volume20-
dc.citation.number2-
dc.citation.startPage82-
dc.citation.endPage87-
dc.identifier.bibliographicCitationCANCER GENE THERAPY, Vol.20(2) : 82-87, 2013-
dc.identifier.rimsid28893-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.